Adaptive Biotechnologies Corporation (ADPT) Dividend History

Company News

• Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

  Adaptive Biotechnologies presented new data on the use of its clonoSEQ test for measurable residual disease (MRD) assessment in various blood cancer types at major medical conferences.

  GlobeNewswire Inc.
• Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide

  The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.

  GlobeNewswire Inc.

  Featured Companies: AMGN BIO BIO.B BMY DGX EXAS GH GILD ILMN LH MDXH MYGN NEO NTRA OPK TECH VCYT
• Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

  The article discusses the promising developments in cancer research, including new therapies and innovative technologies, and highlights recent updates from several biotech companies working on cutting-edge cancer treatments.

  Benzinga

  Featured Companies: ELEV NEO ONCY ORIC
• Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

  Adaptive Biotechnologies presented new data at the ASH Annual Meeting demonstrating the impact of its clonoSEQ test in assessing minimal residual disease (MRD) and informing treatment decisions for various blood cancers.

  GlobeNewswire Inc.
• Laboratory-Developed Tests (LDTs) World Market Forecast Report to 2028, with Coverage of the Effects of the FDA's New "Medical Devices: Laboratory Developed Tests" Rule, Passed in April 2024

  This report analyzes the global market for laboratory-developed tests (LDTs), including the impact of new FDA regulations introduced in 2024. It covers the LDT services market and the market for LDT products sold to clinical laboratories, with a focus on key segments like infectious disease and oncology.

  GlobeNewswire Inc.

  Featured Companies: A BDSX BRKR CDNA DGX GH ILMN LH MDXH MYGN NEO NTRA OPK PACB PKI QGEN TMO WAT